Importantly, in the patient group, the concentrations of IL-33 were elevated in a subset of AML patient samples, indicating that the variability may provide the ability to evaluate for potential relationships between IL-33 levels and clinical outcomes. The gene discussed is IL33; the disease is acute myeloid leukemia.